PNCA
MCID: PNC035
MIFTS: 84

Pancreatic Cancer (PNCA)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Pancreatic Cancer

MalaCards integrated aliases for Pancreatic Cancer:

Name: Pancreatic Cancer 56 12 74 52 73 36 13 54 42 15 37
Pancreatic Carcinoma 56 12 52 73 54 43 15 17 71
Pancreatic Carcinoma, Familial 12 74 71
Familial Pancreatic Carcinoma 52 58 29
Carcinoma of Pancreas 12 29 6
Pancreatic Neoplasm 12 17 71
Malignant Neoplasm of Pancreas 71 32
Pancreatic Acinar Carcinoma 56 73
Familial Pancreatic Cancer 52 58
Cancer of the Pancreas 52 6
Pancreatic Neoplasms 6 43
Pancreatic Tumor 12 54
Malignant Neoplasm of Body of Pancreas 12
Malignant Neoplasm of Head of Pancreas 12
Malignant Neoplasm of Tail of Pancreas 12
Pancreatic Cancer, Susceptibility to 6
Hereditary Pancreatic Carcinoma 52
Pancreatic Carcinoma, Somatic 56
Carcinoma of Head of Pancreas 6
Hereditary Pancreatic Cancer 52
Exocrine Pancreas Carcinoma 12
Pancreatic Cancer, Somatic 56
Neoplasm of the Pancreas 29
Ca Body of Pancreas 12
Ca Head of Pancreas 12
Ca Tail of Pancreas 12
Pancreas Carcinoma 52
Cancer, Pancreatic 39
Pancreas Neoplasm 12
Pancreatic Tumors 15
Exocrine Cancer 12
Pancreas Cancer 52
Pnca 73

Characteristics:

Orphanet epidemiological data:

58
familial pancreatic carcinoma
Inheritance: Multigenic/multifactorial; Age of onset: Adult;

OMIM:

56
Inheritance:
somatic mutation
autosomal dominant
multifactorial

Miscellaneous:
may be seen with other forms of cancer in a family


HPO:

31
pancreatic cancer:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:

Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Disease Ontology 12 DOID:1793 DOID:4905
OMIM 56 260350
KEGG 36 H00019
NCIt 49 C3305 C3850
MESH via Orphanet 44 C535837
ICD10 via Orphanet 33 C25
UMLS via Orphanet 72 C2931038
Orphanet 58 ORPHA1333
MedGen 41 C0235974
UMLS 71 C0030297 C0153458 C0153459 more

Summaries for Pancreatic Cancer

NIH Rare Diseases : 52 Familial pancreatic cancer (FPC) is the occurrence of pancreatic cancer in two or more first-degree relatives (parent and child, or two siblings). It is sometimes referred to as FPC only when there is not a known hereditary cancer syndrome in an affected family. In familial cases, pancreatic cancer often occurs before age 50 (earlier than other forms of pancreatic cancer). In 60% of cases it occurs within the head of the pancreas. Symptoms of pancreatic cancer are generally non-specific and may include pain in the upper abdomen that radiates to the back; loss of appetite; significant weight loss; and jaundice due to bile duct obstruction . Pancreatic cancer often goes undetected until the advanced stages of the disease, and rapid tumor growth and metastasis are common. A specific genetic cause of FPC (in the absence of a known syndrome ) has not been identified. Familial cases of pancreatic cancer due to hereditary conditions may be caused by mutations in any of several genes . Individuals who carry a mutation in one of these genes are often at an increased risk of other types of cancers as well. Currently, only 10-20% of families with FPC will have a mutation identified by genetic testing . Hereditary cancer syndromes and other inherited conditions associated with pancreatic cancer include: BRCA1 hereditary breast and ovarian cancer syndrome BRCA2 hereditary breast and ovarian cancer syndrome Peutz-Jeghers syndrome FAMMM syndrome Lynch syndrome Hereditary pancreatitis In many cases, inheritance of FPC is autosomal dominant ; in some cases, is may be multifactorial . It is important to note that pancreatic cancer itself is not inherited, but a genetic predisposition to developing cancer is inherited. Treatment may include surgical resection , chemotherapy , and/or radiotherapy. Resection is the only potential cure, but most patients have advanced, non-resectable tumors by the time of diagnosis.

MalaCards based summary : Pancreatic Cancer, also known as pancreatic carcinoma, is related to dysplastic nevus syndrome and hereditary breast ovarian cancer syndrome, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Pancreatic Cancer is SMAD4 (SMAD Family Member 4), and among its related pathways/superpathways are Pancreatic cancer and Gastric cancer. The drugs Dalteparin and Thrombin have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, liver and t cells, and related phenotypes are pancreatic adenocarcinoma and abdominal pain

Disease Ontology : 12 An endocrine gland cancer located in the pancreas.

OMIM : 56 Pancreatic cancer shows among the highest mortality rates of any cancer, with a 5-year relative survival rate of less than 5%. By the time of initial diagnosis, metastatic disease is commonly present. Established risk factors include a family history of pancreatic cancer, a medical history of diabetes type 2, and cigarette smoking (summary by Amundadottir et al., 2009). (260350)

MedlinePlus : 42 The pancreas is a gland behind your stomach and in front of your spine. It produces the juices that help break down food and the hormones that help control blood sugar levels. Pancreatic cancer usually begins in the cells that produce the juices. Some risk factors for developing pancreatic cancer include Smoking Long-term diabetes Chronic pancreatitis Certain hereditary disorders Pancreatic cancer is hard to catch early. It doesn't cause symptoms right away. When you do get symptoms, they are often vague or you may not notice them. They include yellowing of the skin and eyes, pain in the abdomen and back, weight loss and fatigue. Also, because the pancreas is hidden behind other organs, health care providers cannot see or feel the tumors during routine exams. Doctors use a physical exam, blood tests, imaging tests, and a biopsy to diagnose it. Because it is often found late and it spreads quickly, pancreatic cancer can be hard to treat. Possible treatments include surgery, radiation, chemotherapy, and targeted therapy. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. NIH: National Cancer Institute

KEGG : 36 Infiltrating ductal adenocarcinoma is the most common malignancy of the pancreas. When most investigators use the term 'pancreatic cancer' they are referring to pancreatic ductal adenocarcinoma (PDA). Normal duct epithelium progresses to infiltrating cancer through a series of histologically defined precursors (PanINs). The overexpression of HER-2/neu and activating point mutations in the K-ras gene occur early, inactivation of the p16 gene at an intermediate stage, and the inactivation of p53, SMAD4, and BRCA2 occur relatively late. Activated K-ras engages multiple effector pathways. Although EGF receptors are conventionally regarded as upstream activators of RAS proteins, they can also act as RAS signal transducers via RAS-induced autocrine activation of the EGFR family ligands. Moreover, PDA shows extensive genomic instability and aneuploidy. Telomere attrition and mutations in p53 and BRCA2 are likely to contribute to these phenotypes. Inactivation of the SMAD4 tumour suppressor gene leads to loss of the inhibitory influence of the transforming growth factor-beta signalling pathway.

UniProtKB/Swiss-Prot : 73 Pancreatic cancer: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

Wikipedia : 74 Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to... more...

Related Diseases for Pancreatic Cancer

Diseases in the Pancreatic Cancer family:

Pancreatic Cancer 1 Pancreatic Cancer 2
Pancreatic Cancer 3 Pancreatic Cancer 4
Pancreatic Cancer 5

Diseases related to Pancreatic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1126)
# Related Disease Score Top Affiliating Genes
1 dysplastic nevus syndrome 35.0 STK11 PALB2 BRCA2 BRCA1
2 hereditary breast ovarian cancer syndrome 34.3 TP53 STK11 PALB2 KRAS BRCA2 BRCA1
3 pancreatic ductal adenocarcinoma 34.2 TP53 SMAD4 MIR96 MIR483 MIR221 MIR21
4 pancreatic adenocarcinoma 34.1 TP53 SMAD4 MIR221 MIR21 MIR155 KRAS
5 rare carcinoma of pancreas 34.1 TP53 STK11 SMAD4 KRAS ACVR1B
6 breast-ovarian cancer, familial 2 33.6 BRCA2 BRCA1
7 adenocarcinoma 33.5 TP53 STK11 SMAD4 KRAS BRCA2
8 pancreatitis 33.3 TP53 SMAD4 MIR21 KRAS BRCA2
9 colorectal cancer 33.2 TP53 STK11 SMAD4 MIR96 MIR483 MIR34C
10 pancreas disease 33.1 TP53 SMAD4 MIR483 MIR34C MIR34A MIR221
11 breast cancer 33.0 TP53 STK11 SMAD4 PALB2 MIR96 MIR34A
12 ovarian cancer 32.9 TP53 STK11 SMAD4 PALB2 MIR34C MIR34B
13 lynch syndrome 32.9 TP53 STK11 SMAD4 PALB2 MIR17 KRAS
14 hepatocellular carcinoma 32.9 TP53 STK11 SMAD4 MIR96 MIR483 MIR34C
15 lung cancer 32.8 TP53 STK11 SMAD4 MIR96 MIR483 MIR34C
16 gastric cancer 32.6 TP53 SMAD4 MIR34A MIR221 MIR21 MIR17
17 prostate cancer 32.5 TP53 SMAD4 MIR96 MIR34A MIR221 MIR21
18 melanoma 32.5 TP53 STK11 MIR96 MIR34C MIR34B MIR34A
19 bladder cancer 32.5 TP53 MIR34A MIR221 MIR21 MIR17 MIR10A
20 esophageal cancer 32.5 TP53 STK11 SMAD4 MIR34A MIR21 MIR155
21 peutz-jeghers syndrome 32.5 TP53 STK11 SMAD4 BRCA2
22 glioblastoma multiforme 32.5 TP53 MIR34A MIR221 MIR21 MIR155 KRAS
23 lung cancer susceptibility 3 32.5 TP53 STK11 SMAD4 MIR96 MIR483 MIR21
24 cholangiocarcinoma 32.4 TP53 SMAD4 MIR21 KRAS
25 body mass index quantitative trait locus 11 32.4 TP53 MIR483 MIR34A MIR21 MIR17 MIR155
26 in situ carcinoma 32.4 TP53 MIR17 BRCA2 BRCA1
27 b-cell lymphoma 32.3 TP53 MIR21 MIR17 MIR15A MIR155 HOTAIR
28 li-fraumeni syndrome 32.2 TP53 STK11 PALB2 MIR483 KRAS BRCA2
29 papillary adenocarcinoma 32.2 TP53 MIR21 KRAS BRCA2 BRCA1
30 melanoma, cutaneous malignant 1 32.2 TP53 STK11 PALB2 BRCA2 BRCA1
31 intrahepatic cholangiocarcinoma 32.2 TP53 SMAD4 KRAS
32 acinar cell carcinoma 32.2 TP53 STK11 SMAD4 BRCA2
33 endometrial cancer 32.2 TP53 SMAD4 MIR34A KRAS HOTAIR BRCA2
34 bile duct cancer 32.1 TP53 SMAD4 MIR483 MIR17 KRAS
35 renal cell carcinoma, nonpapillary 32.1 TP53 MIR34A MIR221 MIR21 MIR17 MIR155
36 wilms tumor 1 32.0 TP53 PALB2 MIR483 MIR15A KRAS BRCA2
37 gastrointestinal system disease 32.0 MIR483 MIR34C MIR34A MIR221 MIR21 MIR17
38 gallbladder cancer 32.0 TP53 SMAD4 KRAS HOTAIR
39 breast ductal carcinoma 32.0 TP53 SMAD4 MIR17 BRCA2 BRCA1
40 retinoblastoma 32.0 TP53 MIR34B MIR34A HOTAIR BRCA2
41 rectum cancer 31.9 MIR483 MIR21 MIR17 KRAS
42 adenosquamous carcinoma 31.9 TP53 SMAD4 KRAS
43 ovarian serous cystadenocarcinoma 31.9 TP53 SMAD4 MIR483 MIR17 KRAS BRCA2
44 glioma 31.9 TP53 MIR34A MIR221 MIR21 MIR17 MIR15A
45 leukemia, chronic lymphocytic 31.9 TP53 MIR483 MIR34A MIR221 MIR21 MIR17
46 leukemia, acute myeloid 31.9 TP53 MIR483 MIR34C MIR34B MIR34A MIR221
47 squamous cell carcinoma, head and neck 31.8 TP53 SMAD4 MIR483 MIR221 MIR21 MIR17
48 endocrine gland cancer 31.8 MIR96 MIR483 MIR34C MIR34A MIR221 MIR21
49 myeloma, multiple 31.8 TP53 MIR483 MIR21 MIR17 MIR15A MIR155
50 kidney cancer 31.7 TP53 MIR21 MIR17 MIR15A HOTAIR

Comorbidity relations with Pancreatic Cancer via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Cholangitis
Cholestasis Deficiency Anemia
Intestinal Obstruction Pancreatic Agenesis 1
Pancreatitis, Hereditary Protein-Energy Malnutrition
Somatostatinoma

Graphical network of the top 20 diseases related to Pancreatic Cancer:



Diseases related to Pancreatic Cancer

Symptoms & Phenotypes for Pancreatic Cancer

Human phenotypes related to Pancreatic Cancer:

58 31 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pancreatic adenocarcinoma 58 31 obligate (100%) Obligate (100%) HP:0006725
2 abdominal pain 58 31 hallmark (90%) Very frequent (99-80%) HP:0002027
3 weight loss 58 31 hallmark (90%) Very frequent (99-80%) HP:0001824
4 exocrine pancreatic insufficiency 58 31 hallmark (90%) Very frequent (99-80%) HP:0001738
5 back pain 58 31 hallmark (90%) Very frequent (99-80%) HP:0003418
6 anorexia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002039
7 chronic fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012432
8 poor appetite 58 31 hallmark (90%) Very frequent (99-80%) HP:0004396
9 jaundice 58 31 frequent (33%) Frequent (79-30%) HP:0000952
10 extrahepatic cholestasis 58 31 frequent (33%) Frequent (79-30%) HP:0012334
11 lymphadenopathy 58 31 frequent (33%) Frequent (79-30%) HP:0002716
12 functional intestinal obstruction 58 31 frequent (33%) Frequent (79-30%) HP:0005249
13 intestinal pseudo-obstruction 58 31 frequent (33%) Frequent (79-30%) HP:0004389
14 nausea and vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002017
15 diabetes mellitus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000819
16 elevated hepatic transaminase 58 31 occasional (7.5%) Occasional (29-5%) HP:0002910
17 melanoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0002861
18 colon cancer 58 31 occasional (7.5%) Occasional (29-5%) HP:0003003
19 breast carcinoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0003002
20 hepatosplenomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0001433
21 neoplasm of the liver 58 31 occasional (7.5%) Occasional (29-5%) HP:0002896
22 intermittent diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002254
23 ovarian carcinoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0025318
24 peritoneal abscess 58 31 occasional (7.5%) Occasional (29-5%) HP:0100592
25 neoplasm of the pancreas 31 HP:0002894
26 increased level of l-fucose in urine 31 HP:0410067

Symptoms via clinical synopsis from OMIM:

56
Abdomen Pancreas:
pancreatic cancer
pancreatic ductal adenocarcinoma

Neoplasia:
pancreatic ductal adenocarcinoma

Clinical features from OMIM:

260350

UMLS symptoms related to Pancreatic Cancer:


nausea and vomiting, constipation, abdominal pain, pruritus, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Pancreatic Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 BRCA1 BRCA2 KRAS PALB2 SMAD4 STK11

Drugs & Therapeutics for Pancreatic Cancer

Drugs for Pancreatic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 711)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dalteparin Approved Phase 4 9005-49-6
2
Thrombin Approved, Investigational Phase 4
3
Nicotine Approved Phase 4 54-11-5 942 89594
4
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
5
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
6
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
7
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
8
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
9
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
10
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
11
Glycolic acid Approved, Investigational Phase 4 79-14-1 757
12
Pasireotide Approved Phase 4 396091-73-9 9941444
13
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
14
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
15
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
16
Histamine Approved, Investigational Phase 4 51-45-6 774
17
Metronidazole Approved Phase 4 443-48-1 4173
18
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
19
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
21
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
22
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
23
Morphine Approved, Investigational Phase 4 57-27-2 5288826
24
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
25
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
26
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
27
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
28
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
29
Nimotuzumab Investigational Phase 4 780758-10-3, 828933-61-3
30 Flurbiprofen axetil Investigational Phase 4 91503-79-6
31 Parenteral Nutrition Solutions Phase 4
32 Fibrin Tissue Adhesive Phase 4
33 Soybean oil, phospholipid emulsion Phase 4
34 Fat Emulsions, Intravenous Phase 4
35 Dermatologic Agents Phase 4
36 Hemostatics Phase 4
37 Central Nervous System Stimulants Phase 4
38 Nicotinic Agonists Phase 4
39 Cytochrome P-450 Enzyme Inhibitors Phase 4
40 Dopamine Uptake Inhibitors Phase 4
41 Dopamine Agents Phase 4
42 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
43 Hypnotics and Sedatives Phase 4
44 Ferric Compounds Phase 4
45 Keratolytic Agents Phase 4
46 Adrenergic Agonists Phase 4
47 Adrenergic alpha-2 Receptor Agonists Phase 4
48 Hydrocortisone hemisuccinate Phase 4
49 Hydrocortisone 17-butyrate 21-propionate Phase 4
50 Hydrocortisone-17-butyrate Phase 4

Interventional clinical trials:

(show top 50) (show all 2590)
# Name Status NCT ID Phase Drugs
1 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
2 Prospective Paired Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms Unknown status NCT01673334 Phase 4
3 The Effect of Application of Fibrinogen/Thrombin-coated Collagen Patch (TachoSil®) in Pancreaticojejunostomy for Prevention of Pancreatic Fistula After Pancreatoduodenectomy Unknown status NCT03269955 Phase 4 Fibrinogen/thrombin-coated collagen patch
4 Additional Effects of Perioperative Immunonutrition on Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
5 A Randomized, Controlled, Double Blind, Multicenter Study of Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Advanced or Metastatic Pancreatic Cancer After First-line Treatment Unknown status NCT02945267 Phase 4 Nimotuzumab plus S1;Placebo plus S1
6 A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia Unknown status NCT02553187 Phase 4 Kanglaite Injection
7 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
8 Randomized Clinical Trial of Omega-3 Fatty Acid-supplemented Parenteral Nutrition Versus Standard Parenteral Nutrition in Patients Undergoing Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
9 Randomized Controlled Trial Comparing Covered and Uncovered Biliary Self Expanding Metal Stents (SEMS) for Pre-operative Drainage During Neoadjuvant Therapy in Patients With Pancreatic Cancer Completed NCT02238847 Phase 4
10 Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells? Completed NCT02335151 Phase 4 Desflurane
11 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
12 Improved Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI) Completed NCT00920023 Phase 4 Superparamagnetic Iron Oxide Magnetic Resonance Imaging
13 Prospective Randomized Trial Comparing Covered Metal Stents Placed Above and Across the Sphincter of Oddi in Malignant Biliary Obstruction: A Multi-nation, Multi-center Study Completed NCT01041612 Phase 4
14 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) With Alcohol in Patients With Locally Advanced and Unresectable Pancreatic Adenocarcinoma: A Randomized Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
15 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
16 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
17 Randomized Clinical Trial of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Undergoing Chemotherapy Treatment. Completed NCT00966277 Phase 4 Dalteparin
18 A Prospective Study of Celiac Block Technique: One Injection or Two? Completed NCT00583479 Phase 4
19 A Prospective Multi-center Randomized Study of the Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
20 A SINGLE-ARM OPEN-LABEL INTERNATIONAL MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT (REGISTERED)) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL-DIFFERENTIATED UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS Completed NCT01525550 Phase 4 sunitinib
21 Pilot Study: Randomized Controlled Trial on the Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
22 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
23 Effects of Dexmedetomidine on Anaesthesia During IRE Procedures for Solid Tumours Completed NCT02044224 Phase 4 Dexmedetomidine
24 The Importance of Albumin Infusion Rate for Plasma Volume Expansion. AIR. A Phase III Assessor Blinded Parallel Group Randomized Study Completed NCT02728921 Phase 4 5% Albumin infusion 30 min;5% Albumin infusion 3 hours
25 Use of Polyethylene Glycolic Acid or Tachocomb to Prevent Pancreatic Fistula Following Distal Pancreatectomy: Prospective Multicenter Randomized Study Completed NCT01550406 Phase 4
26 Randomized Multi-Center Study Comparing No Drainage to Preoperative Biliary Drainage Using Metal Stents in Patients With Resectable Pancreatic or Periampullary Cancer Recruiting NCT01774019 Phase 4
27 Effect of Perioperative Epidural Block and Dexamethasone on Outcome of Patients Undergoing Pancreatic Cancer Surgery Recruiting NCT04025840 Phase 4 Dexamethasone
28 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Recruiting NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
29 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial Recruiting NCT01642875 Phase 4
30 A Dose Escalation Safety Study of Locally-Delivered (Intra-Arterial) Gemcitabine in Unresectable Adenocarcinoma of the Pancreas Active, not recruiting NCT02237157 Phase 4 Gemcitabine, local delivery
31 HYPAR Trial - Hydrocortisone vs Pasireotide in Reducing Pancreatic Fistula and Other Complications After Pancreatic Resection - a Prospective, Randomized, Controlled Trial Active, not recruiting NCT02775227 Phase 4 Hydrocortisone;Pasireotide
32 A Multicenter Phase 4 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Active, not recruiting NCT02812992 Phase 4 Nab-paclitaxel;Gemcitabine
33 H.O.P.E. Healing Optimization Through Preoperative Engagement: A Prospective Single Cohort Study to Evaluate the Effect of a Prehabilitation Program on Preoperative Outcomes in Upper GI Surgical Oncology Patients Enrolling by invitation NCT03642093 Phase 4
34 Creon (Pancrelipase) Therapy for Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Pancreatic Cancer: A Double-blind, Randomized, Parallel Design With 2 Dose Cohorts of Pancrelipase in Resected Pancreatic Cancer Subjects and an Open-label Single Dose Cohort in Non-resected Pancreatic Cancer Subjects Not yet recruiting NCT03859869 Phase 4 Pancrelipase;Placebo
35 A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma Not yet recruiting NCT03891979 Phase 4 Antibiotics and Pembrolizumab
36 Assessing Quality of Life and the Feasibility of a Nutrition and Pharmacological Algorithm for Oncology Patients With Anorexia Not yet recruiting NCT04155008 Phase 4 Dexamethasone;Dronabinol;Mirtazapine
37 Glycocalyx Levels in Patients Undergoing Pancreatectomy With Human Albumin 5% vs. Gelofusine Not yet recruiting NCT04058236 Phase 4
38 An Open Label Study to Evaluate the Effect of First Line Treatment With Tarceva in Combination With Gemcitabine on Overall Survival and Disease Progression in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer Terminated NCT00642733 Phase 4 erlotinib [Tarceva];gemcitabine
39 Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study Terminated NCT01768988 Phase 4 Placebo;Pregabalin
40 Quality of Life After Bilioenteric Anastomosis in Comparison to Endoscopically Placed Stents in Patients With Unresectable Pancreatic Cancer and Jaundice Terminated NCT01887041 Phase 4
41 Impact of Perioperative Dexamethasone and Flurbiprofen Axetil on Long-term Survival After Surgery for Non-small Cell Lung Cancer: A 2x2 Factorial Randomized Controlled Trial Terminated NCT03172988 Phase 4 Dexamethasone;Normal saline;Flurbiprofen axetil;Lipid microsphere
42 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Withdrawn NCT02570529 Phase 4 Albis®;Placebo
43 Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy Withdrawn NCT01401387 Phase 4
44 CROSSFIRE Trial: Crossatlantic Randomized Controlled Trial Comparing Outcome in Survival After Systemic Plus Focal Therapy for Inoperable Pancreatic Carcinoma: Radiotherapy Versus Irreversible Electroporation Unknown status NCT02791503 Phase 2, Phase 3
45 A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer Unknown status NCT02043288 Phase 3 NC-6004;Gemcitabine
46 Phase III Randomized, Double-blind Study Comparing Gemcitabine and Sorafenib or a Placebo in Patients With Locally Advanced or Metastatic Cancer of the Pancreas. Unknown status NCT00541021 Phase 3 gemcitabine hydrochloride;sorafenib tosylate
47 Randomized Phase III Trial With Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine in Patients With Advanced Pancreatic Cancer Unknown status NCT00440167 Phase 3 Gemcitabine;Capecitabine;Erlotinib
48 Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus Most Appropriate Therapy in Refractory Pancreatic Cancer Patients Unknown status NCT00005870 Phase 3 fluorouracil;gemcitabine hydrochloride;mitomycin C;rubitecan
49 Implementation of Electroporation - NanoKnife as Treatment for Advanced Pancreatic Cancer. Unknown status NCT02079623 Phase 3
50 A Prospective, Randomized, Controlled, Double-blind, Multi-center Clinical Study of Nimotuzumab Combinated With Gemcitabine Contrast to Placebo Combinated With Gemcitabine in K-RAS Wild-type,Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine

Search NIH Clinical Center for Pancreatic Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


docetaxel
Fluorouracil
Ifosfamide
irinotecan
Irinotecan hydrochloride
Octreotide
Octreotide Acetate
sunitinib
sunitinib malate
Tamoxifen
Tamoxifen Citrate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Pancreatic Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Pancreatic Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Pancreatic Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 21498393 22996367 19304471 22555974 15800326 23650429 21325070 8170938 12242449 24218514 23904171

Cochrane evidence based reviews: pancreatic neoplasms

Genetic Tests for Pancreatic Cancer

Genetic tests related to Pancreatic Cancer:

# Genetic test Affiliating Genes
1 Carcinoma of Pancreas 29 KRAS SMAD4 STK11
2 Familial Pancreatic Carcinoma 29
3 Neoplasm of the Pancreas 29

Anatomical Context for Pancreatic Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreatic Cancer:

19
Pancreas

MalaCards organs/tissues related to Pancreatic Cancer:

40
Pancreas, Liver, T Cells, Breast, Lung, Testes, Lymph Node
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Cancer:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Acini Acinar Cells

Publications for Pancreatic Cancer

Articles related to Pancreatic Cancer:

(show top 50) (show all 35192)
# Title Authors PMID Year
1
Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. 54 61 56 6
18762988 2008
2
ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. 54 61 6
11248065 2001
3
DPC4 gene in various tumor types. 54 61 6
8653691 1996
4
MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. 54 61 56
7845688 1995
5
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. 54 61 56
7726912 1994
6
p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. 54 61 6
8513440 1993
7
The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. 61 56
31221853 2019
8
Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. 61 56
30996350 2019
9
Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. 61 56
30918400 2019
10
Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. 61 56
28099419 2017
11
A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. 61 56
27732578 2016
12
Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. 61 56
27213290 2016
13
Genomic analyses identify molecular subtypes of pancreatic cancer. 61 56
26909576 2016
14
Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. 61 56
26168401 2015
15
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. 61 56
26106858 2015
16
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. 61 56
25356972 2015
17
Whole genomes redefine the mutational landscape of pancreatic cancer. 61 56
25719666 2015
18
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. 61 56
23535601 2013
19
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. 61 56
23103869 2012
20
CDKN2A is the main susceptibility gene in Italian pancreatic cancer families. 61 56
22368299 2012
21
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. 61 56
21436454 2011
22
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. 61 56
20981101 2010
23
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. 61 56
20981102 2010
24
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. 61 56
20101243 2010
25
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. 61 56
19648918 2009
26
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. 54 61 46
19714243 2009
27
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. 61 56
19460966 2009
28
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. 61 6
19264984 2009
29
Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. 54 61 46
19407485 2009
30
The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. 61 6
17415588 2007
31
Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. 61 6
17194196 2006
32
Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. 61 56
15912495 2005
33
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. 61 56
14520413 2003
34
Progression model for pancreatic cancer. 61 56
10955772 2000
35
Inheritance of pancreatic cancer in pancreatic cancer-prone families. 61 56
10872424 2000
36
Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. 61 6
10362809 1999
37
Characterization of a carboxy-terminal BRCA1 interacting protein. 61 6
9811458 1998
38
Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. 61 56
9091646 1997
39
Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. 61 56
7666917 1995
40
Familial pancreatic adenocarcinoma: association with diabetes and early molecular diagnosis. 61 56
7616537 1995
41
Medical genetic study of eight pancreatic cancer-prone families. 61 56
7874567 1995
42
Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma. 61 6
8439212 1993
43
Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. 61 56
3828965 1987
44
Pancreatic cancer in father and son. 61 56
67325 1977
45
Familial carcinoma of the pancreas. 61 56
1269168 1976
46
Influence of non-jaundice stage at diagnosis on clinicopathological features and long-term survival of patients with periampullary carcinomas. 61 42
31702620 2019
47
The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. 56
27049944 2016
48
A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. 6
25394175 2015
49
The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma. 56
24859531 2014
50
American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. 6
24493721 2014

Variations for Pancreatic Cancer

ClinVar genetic disease variations for Pancreatic Cancer:

6 (show top 50) (show all 150) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 STK11 NM_000455.4(STK11):c.108C>A (p.Tyr36Ter)SNV Pathogenic 7452 rs137853079 19:1207020-1207020 19:1207021-1207021
2 STK11 NM_000455.4(STK11):c.650del (p.Pro217fs)deletion Pathogenic 7453 rs397518442 19:1220629-1220629 19:1220630-1220630
3 STK11 NM_000455.4(STK11):c.936del (p.Lys312fs)deletion Pathogenic 7454 rs397518443 19:1222997-1222997 19:1222998-1222998
4 ACVR1B NM_004302.5(ACVR1B):c.1159_1163del (p.Asp387fs)deletion Pathogenic 8227 rs387906389 12:52380624-52380628 12:51986840-51986844
5 ACVR1B NM_004302.5(ACVR1B):c.1262-502_1392+24deldeletion Pathogenic 8228 rs1555162597 12:52385141-52385797 12:51991357-51992013
6 SMAD4 NM_005359.5(SMAD4):c.1072G>T (p.Gly358Ter)SNV Pathogenic 8536 rs121912576 18:48591909-48591909 18:51065539-51065539
7 SMAD4 NM_005359.5(SMAD4):c.1477G>C (p.Asp493His)SNV Pathogenic 8538 rs121912578 18:48604655-48604655 18:51078285-51078285
8 SMAD4 NM_005359.5(SMAD4):c.1543A>T (p.Arg515Ter)SNV Pathogenic 8539 rs121912579 18:48604721-48604721 18:51078351-51078351
9 TP53 NM_000546.5(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
10 TP53 NM_000546.5(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
11 TP53 NM_000546.5(TP53):c.105G>T (p.Leu35Phe)SNV Pathogenic 12371 rs121912661 17:7579582-7579582 17:7676264-7676264
12 TP53 NM_000546.5(TP53):c.524G>A (p.Arg175His)SNV Pathogenic 12374 rs28934578 17:7578406-7578406 17:7675088-7675088
13 KRAS NM_004985.5(KRAS):c.35G>A (p.Gly12Asp)SNV Pathogenic 12582 rs121913529 12:25398284-25398284 12:25245350-25245350
14 KRAS NM_004985.5(KRAS):c.35G>T (p.Gly12Val)SNV Pathogenic 12583 rs121913529 12:25398284-25398284 12:25245350-25245350
15 KRAS NM_033360.4(KRAS):c.*12A>TSNV Pathogenic 12587 rs104894360 12:25362838-25362838 12:25209904-25209904
16 BRCA1 NM_007294.3(BRCA1):c.5266dupC (p.Gln1756Profs)duplication Pathogenic 17677 rs80357906 17:41209079-41209080 17:43057062-43057063
17 SMAD4 NM_005359.5(SMAD4):c.1082G>A (p.Arg361His)SNV Pathogenic 24832 rs377767347 18:48591919-48591919 18:51065549-51065549
18 SMAD4 NM_005359.5(SMAD4):c.1236C>G (p.Tyr412Ter)SNV Pathogenic 24845 rs121912577 18:48593485-48593485 18:51067115-51067115
19 SMAD4 NM_005359.5(SMAD4):c.1498A>G (p.Ile500Val)SNV Pathogenic 30150 rs281875322 18:48604676-48604676 18:51078306-51078306
20 BRCA2 NM_000059.3(BRCA2):c.6405_6409del (p.Asn2135fs)deletion Pathogenic 38043 rs80359584 13:32914894-32914898 13:32340757-32340761
21 BRCA2 NM_000059.3(BRCA2):c.4525C>T (p.Gln1509Ter)SNV Pathogenic 51659 rs80358683 13:32913017-32913017 13:32338880-32338880
22 BRCA2 NM_000059.3(BRCA2):c.6408_6414del (p.Asn2137fs)deletion Pathogenic 52086 rs397507851 13:32914898-32914904 13:32340761-32340767
23 PALB2 NM_024675.3(PALB2):c.2167_2168del (p.Met723fs)deletion Pathogenic 136132 rs587776416 16:23641307-23641308 16:23629986-23629987
24 SMAD4 NM_005359.5(SMAD4):c.1245_1248delCAGA (p.Asp415Glufs)deletion Pathogenic 142253 rs80338965 18:48593491-48593494 18:51067121-51067124
25 PALB2 NM_024675.3(PALB2):c.1652dup (p.Tyr551Ter)duplication Pathogenic 560017 rs1555461176 16:23646214-23646215 16:23634893-23634894
26 TMEM71 , TSC1 t(8;9)(q24.22;q34.13)Translocation Pathogenic 625198 8:133731583-133731584
27 TP53 NM_000546.5(TP53):c.559+1G>ASNV Pathogenic/Likely pathogenic 428908 rs1131691042 17:7578370-7578370 17:7675052-7675052
28 TP53 NM_000546.5(TP53):c.96+1G>TSNV Pathogenic/Likely pathogenic 482212 rs1131691003 17:7579699-7579699 17:7676381-7676381
29 STK11 NM_000455.4(STK11):c.582C>G (p.Asp194Glu)SNV Likely pathogenic 376187 rs786202134 19:1220489-1220489 19:1220490-1220490
30 TTK NM_003318.5(TTK):c.2089G>T (p.Asp697Tyr)SNV Likely pathogenic 376700 rs1057520011 6:80747723-80747723 6:80038006-80038006
31 NEK8 NM_178170.3(NEK8):c.589G>C (p.Ala197Pro)SNV Likely pathogenic 376707 rs756231248 17:27062360-27062360 17:28735342-28735342
32 STK33 NM_030906.4(STK33):c.969T>G (p.Phe323Leu)SNV Likely pathogenic 376702 rs1057520013 11:8457665-8457665 11:8436118-8436118
33 TP53 NM_000546.5(TP53):c.799C>T (p.Arg267Trp)SNV Likely pathogenic 141764 rs55832599 17:7577139-7577139 17:7673821-7673821
34 STK11 NM_000455.4(STK11):c.719C>G (p.Ser240Trp)SNV Likely pathogenic 182902 rs730881976 19:1220701-1220701 19:1220702-1220702
35 STK11 NM_000455.4(STK11):c.582C>A (p.Asp194Glu)SNV Likely pathogenic 185384 rs786202134 19:1220489-1220489 19:1220490-1220490
36 SMAD4 NM_005359.5(SMAD4):c.677C>T (p.Ala226Val)SNV Conflicting interpretations of pathogenicity 182869 rs539739051 18:48584504-48584504 18:51058134-51058134
37 STK11 NM_000455.4(STK11):c.632G>A (p.Arg211Gln)SNV Conflicting interpretations of pathogenicity 182910 rs730881982 19:1220614-1220614 19:1220615-1220615
38 BRCA2 NM_000059.3(BRCA2):c.6325G>A (p.Val2109Ile)SNV Conflicting interpretations of pathogenicity 41560 rs79456940 13:32914817-32914817 13:32340680-32340680
39 BRCA2 NM_000059.3(BRCA2):c.10150C>T (p.Arg3384Ter)SNV Conflicting interpretations of pathogenicity 51049 rs397507568 13:32972800-32972800 13:32398663-32398663
40 PALLD NM_001166108.2(PALLD):c.2199+8G>ASNV Conflicting interpretations of pathogenicity 136011 rs200060953 4:169815836-169815836 4:168894685-168894685
41 PALLD NM_001166108.2(PALLD):c.2393T>C (p.Met798Thr)SNV Conflicting interpretations of pathogenicity 136014 rs142116575 4:169819786-169819786 4:168898635-168898635
42 BRCA2 NM_000059.3(BRCA2):c.353G>A (p.Arg118His)SNV Conflicting interpretations of pathogenicity 37845 rs80358603 13:32899249-32899249 13:32325112-32325112
43 PALLD NM_001166108.2(PALLD):c.909A>T (p.Arg303Ser)SNV Conflicting interpretations of pathogenicity 128115 rs138897963 4:169589341-169589341 4:168668190-168668190
44 BRCA2 NM_000059.3(BRCA2):c.7522G>A (p.Gly2508Ser)SNV Conflicting interpretations of pathogenicity 52347 rs80358978 13:32930651-32930651 13:32356514-32356514
45 BRCA1 NM_007300.4(BRCA1):c.811G>A (p.Val271Met)SNV Conflicting interpretations of pathogenicity 55720 rs80357244 17:41246737-41246737 17:43094720-43094720
46 BRCA2 NM_000059.3(BRCA2):c.1568A>G (p.His523Arg)SNV Conflicting interpretations of pathogenicity 96766 rs80358443 13:32907183-32907183 13:32333046-32333046
47 BRCA1 NM_007294.3(BRCA1):c.3327_3329del (p.Lys1110del)deletion Conflicting interpretations of pathogenicity 125625 rs80357575 17:41244219-41244221 17:43092202-43092204
48 TP53 NM_000546.5(TP53):c.466C>T (p.Arg156Cys)SNV Conflicting interpretations of pathogenicity 127810 rs563378859 17:7578464-7578464 17:7675146-7675146
49 PALLD NM_001166108.2(PALLD):c.1040C>T (p.Thr347Met)SNV Conflicting interpretations of pathogenicity 128094 rs150711066 4:169589472-169589472 4:168668321-168668321
50 PALLD NM_001166108.2(PALLD):c.1273A>T (p.Thr425Ser)SNV Conflicting interpretations of pathogenicity 128095 rs140454899 4:169606648-169606648 4:168685497-168685497

Cosmic variations for Pancreatic Cancer:

9 (show top 50) (show all 355)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM90142044 TRAF7 pancreas,NS,carcinoma,acinar carcinoma c.1187A>G p.Q396R 16:2173972-2173972 63
2 COSM84313984 TRAF2 pancreas,NS,carcinoma,acinar carcinoma c.876G>T p.E292D 9:136920431-136920431 63
3 COSM100986702 SPOP pancreas,NS,carcinoma,acinar carcinoma c.838-1G>A p.? 17:49602008-49602008 63
4 COSM89661338 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 63
5 COSM91386650 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1600C>T p.Q534* 18:51078408-51078408 63
6 COSM91381131 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1597C>A p.L533I 18:51078405-51078405 63
7 COSM91388156 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1156G>C p.G386R 18:51067035-51067035 63
8 COSM103029577 SETD2 pancreas,NS,carcinoma,acinar carcinoma c.4325C>A p.S1442* 3:47120311-47120311 63
9 COSM88247526 RPTOR pancreas,NS,carcinoma,acinar carcinoma c.485G>A p.G162E 17:80707977-80707977 63
10 COSM93857613 ROS1 pancreas,NS,carcinoma,acinar carcinoma c.5756C>A p.A1919D 6:117321280-117321280 63
11 COSM86830145 RARA pancreas,NS,carcinoma,acinar carcinoma c.995T>A p.I332N 17:40354489-40354489 63
12 COSM86828778 RARA pancreas,NS,carcinoma,acinar carcinoma c.1285G>T p.G429C 17:40356122-40356122 63
13 COSM101884299 PTPRD pancreas,NS,carcinoma,acinar carcinoma c.5594G>C p.R1865T 9:8319907-8319907 63
14 COSM96847630 PTEN pancreas,NS,carcinoma,acinar carcinoma c.686C>A p.S229* 10:87957904-87957904 63
15 COSM96849216 PTEN pancreas,NS,carcinoma,acinar carcinoma c.740T>A p.L247* 10:87957958-87957958 63
16 COSM135336051 PLCG2 pancreas,NS,carcinoma,acinar carcinoma c.2462C>A p.S821Y 16:81927126-81927126 63
17 COSM135340255 PLCG2 pancreas,NS,carcinoma,acinar carcinoma c.3622G>A p.E1208K 16:81956746-81956746 63
18 COSM87132308 PIK3CA pancreas,NS,carcinoma,acinar carcinoma c.1633G>A p.E545K 3:179218303-179218303 63
19 COSM101247044 PBRM1 pancreas,NS,carcinoma,acinar carcinoma c.2884G>T p.D962Y 3:52589151-52589151 63
20 COSM98760653 PAK5 pancreas,NS,carcinoma,acinar carcinoma c.1657C>A p.L553M 20:9557694-9557694 63
21 COSM89882616 NKX2-1 pancreas,NS,carcinoma,acinar carcinoma c.668A>T p.H223L 14:36517816-36517816 63
22 COSM100296764 NFE2L2 pancreas,NS,carcinoma,acinar carcinoma c.838G>T p.D280Y 2:177231765-177231765 63
23 COSM93653608 NF1 pancreas,NS,carcinoma,acinar carcinoma c.7786G>T p.V2596F 17:31357007-31357007 63
24 COSM133111711 LATS1 pancreas,NS,carcinoma,acinar carcinoma c.3106A>G p.T1036A 6:149662016-149662016 63
25 COSM87804005 KRAS pancreas,NS,carcinoma,acinar carcinoma c.35G>A p.G12D 12:25245350-25245350 63
26 COSM87804055 KRAS pancreas,NS,carcinoma,acinar carcinoma c.35G>T p.G12V 12:25245350-25245350 63
27 COSM87804028 KRAS pancreas,NS,carcinoma,acinar carcinoma c.38G>A p.G13D 12:25245347-25245347 63
28 COSM87691551 KMT2D pancreas,NS,carcinoma,acinar carcinoma c.9997C>T p.Q3333* 12:49037359-49037359 63
29 COSM87662991 KMT2D pancreas,NS,carcinoma,acinar carcinoma c.10900C>T p.Q3634* 12:49033805-49033805 63
30 COSM124276538 INPP4B pancreas,NS,carcinoma,acinar carcinoma c.292T>G p.F98V 4:142403018-142403018 63
31 COSM139991052 IKBKE pancreas,NS,carcinoma,acinar carcinoma c.1956G>T p.Q652H 1:206493289-206493289 63
32 COSM103033796 IDH1 pancreas,NS,carcinoma,acinar carcinoma c.394C>T p.R132C 2:208248389-208248389 63
33 COSM142296522 H3C2 pancreas,NS,carcinoma,acinar carcinoma c.258G>C p.Q86H 6:26031803-26031803 63
34 COSM91457259 GSK3B pancreas,NS,carcinoma,acinar carcinoma c.197C>A p.S66* 3:120002131-120002131 63
35 COSM99128434 GRIN2A pancreas,NS,carcinoma,acinar carcinoma c.527T>A p.I176N 16:9938439-9938439 63
36 COSM93760887 GNAS pancreas,NS,carcinoma,acinar carcinoma c.2531G>A p.R844H 20:58909366-58909366 63
37 COSM86228419 FGF19 pancreas,NS,carcinoma,acinar carcinoma c.574C>A p.L192M 11:69699339-69699339 63
38 COSM110406511 FAT1 pancreas,NS,carcinoma,acinar carcinoma c.11216C>T p.A3739V 4:186603310-186603310 63
39 COSM116522793 ENSG00000282218 pancreas,NS,carcinoma,acinar carcinoma c.662C>A p.A221D 6:117321280-117321280 63
40 COSM86805375 EGFR pancreas,NS,carcinoma,acinar carcinoma c.3541G>C p.A1181P 7:55205525-55205525 63
41 COSM90966672 EED pancreas,NS,carcinoma,acinar carcinoma c.445A>T p.T149S 11:86256405-86256405 63
42 COSM150913596 CTNNB1 pancreas,NS,carcinoma,acinar carcinoma c.122C>T p.T41I 3:41224634-41224634 63
43 COSM150913731 CTNNB1 pancreas,NS,carcinoma,acinar carcinoma c.110C>G p.S37C 3:41224622-41224622 63
44 COSM150913542 CTNNB1 pancreas,NS,carcinoma,acinar carcinoma c.134C>T p.S45F 3:41224646-41224646 63
45 COSM150913552 CTNNB1 pancreas,NS,carcinoma,acinar carcinoma c.100G>A p.G34R 3:41224612-41224612 63
46 COSM150913745 CTNNB1 pancreas,NS,carcinoma,acinar carcinoma c.134C>G p.S45C 3:41224646-41224646 63
47 COSM88820590 CD276 pancreas,NS,carcinoma,acinar carcinoma c.308G>T p.G103V 15:73702483-73702483 63
48 COSM88436431 AXIN2 pancreas,NS,carcinoma,acinar carcinoma c.1665C>A p.C555* 17:65537371-65537371 63
49 COSM84165684 AXIN1 pancreas,NS,carcinoma,acinar carcinoma c.1210G>T p.E404* 16:304348-304348 63
50 COSM97563963 ATRX pancreas,NS,carcinoma,acinar carcinoma c.5438G>A p.G1813E 23:77618816-77618816 63

Copy number variations for Pancreatic Cancer from CNVD:

7 (show top 50) (show all 15981)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13839 1 100027661 100101597 Gain and loss AGL Pancreatic cancer
2 13849 1 100147561 100201027 Gain and loss SLC35A3 Pancreatic cancer
3 13857 1 100215810 100260948 Gain and loss HIAT1 Pancreatic cancer
4 13861 1 100261125 100310532 Gain and loss SASS6 Pancreatic cancer
5 13862 1 10027309 10175557 Gain and loss UBE4B Pancreatic cancer
6 13871 1 100326522 100355822 Gain and loss LRRC39 Pancreatic cancer
7 13875 1 100372897 100427397 Gain and loss DBT Pancreatic cancer
8 13880 1 100443784 100469348 Gain and loss RTCD1 Pancreatic cancer
9 13887 1 100530068 100697853 Gain and loss CDC14A Pancreatic cancer
10 13901 1 100715714 100719589 Gain and loss GPR88 Pancreatic cancer
11 13916 1 100897318 100916618 Gain and loss VCAM1 Pancreatic cancer
12 13924 1 101049969 101073575 Gain and loss EXTL2 Pancreatic cancer
13 13925 1 101073653 101157013 Gain and loss SLC30A7 Pancreatic cancer
14 13931 1 101167641 101203392 Gain and loss DPH5 Pancreatic cancer
15 13942 1 101414596 101419094 Gain and loss EDG1 Pancreatic cancer
16 13966 1 101980154 102174569 Gain and loss OLFM3 Pancreatic cancer
17 13979 1 10205097 10375920 Gain and loss KIF1B Pancreatic cancer
18 14027 1 103055016 103286073 Gain and loss COL11A1 Pancreatic cancer
19 14059 1 103780424 103834168 Gain and loss RNPC3 Pancreatic cancer
20 14081 1 103871529 103880389 Gain and loss AMY2A Pancreatic cancer
21 14091 1 103910910 103919188 Gain and loss AMY1A Pancreatic cancer
22 14093 1 10393351 10414467 Gain and loss PGD Pancreatic cancer
23 14151 1 10424425 10446476 Gain and loss APITD1 Pancreatic cancer
24 14168 1 10454871 10466879 Gain and loss DFFA Pancreatic cancer
25 14176 1 10469278 10625079 Gain and loss PEX14 Pancreatic cancer
26 14277 1 10641535 10790973 Gain and loss CASZ1 Pancreatic cancer
27 14348 1 107311380 107313956 Gain and loss HRMT1L6 Pancreatic cancer
28 14354 1 107395591 107665249 Gain and loss NTNG1 Pancreatic cancer
29 14396 1 107825832 108219580 Gain and loss VAV3 Pancreatic cancer
30 14412 1 107915304 108309068 Gain or loss VAV3 Pancreas cancer
31 14435 1 108389491 108454940 Gain and loss SLC25A24 Pancreatic cancer
32 14445 1 108477129 108498715 Gain and loss NBPF4 Pancreatic cancer
33 14472 1 108630504 108640564 Gain and loss NBPF5 Pancreatic cancer
34 14486 1 108815093 108889808 Gain and loss FAM102B Pancreatic cancer
35 14495 1 108947005 108956462 Gain and loss PRPF38B Pancreatic cancer
36 14496 1 108977028 108997407 Gain and loss FNDC7 Pancreatic cancer
37 14498 1 109001350 109064190 Gain and loss STXBP3 Pancreatic cancer
38 14509 1 109131869 109185060 Gain and loss GPSM2 Pancreatic cancer
39 14514 1 109184172 109218121 Gain and loss CLCC1 Pancreatic cancer
40 14518 1 109224882 109296777 Gain and loss WDR47 Pancreatic cancer
41 14530 1 109319187 109330611 Gain and loss TAF13 Pancreatic cancer
42 14538 1 109368575 109461639 Gain and loss KIAA1324 Pancreatic cancer
43 14554 1 109468582 109492827 Gain and loss SARS Pancreatic cancer
44 14558 1 109504683 109530414 Gain and loss CELSR2 Pancreatic cancer
45 14588 1 109568465 109652615 Gain and loss SORT1 Pancreatic cancer
46 14603 1 109594163 109619901 Gain or loss CELSR2 Pancreas cancer
47 14615 1 109656520 109681079 Gain and loss PSMA5 Pancreatic cancer
48 14617 1 109721142 109734212 Gain and loss SYPL2 Pancreatic cancer
49 14619 1 109738603 109747396 Gain and loss ATXN7L2 Pancreatic cancer
50 14623 1 109748763 109755097 Gain and loss CYB561D1 Pancreatic cancer

Expression for Pancreatic Cancer

Search GEO for disease gene expression data for Pancreatic Cancer.

Pathways for Pancreatic Cancer

Pathways related to Pancreatic Cancer according to KEGG:

36
# Name Kegg Source Accession
1 Pancreatic cancer hsa05212

GO Terms for Pancreatic Cancer

Cellular components related to Pancreatic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lateral element GO:0000800 8.62 BRCA2 BRCA1

Biological processes related to Pancreatic Cancer according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 10.02 TP53 STK11 PALB2 MIR34A BRCA2 BRCA1
2 negative regulation of cell proliferation GO:0008285 9.99 TP53 STK11 SMAD4 MIR221 MIR21 MIR15A
3 in utero embryonic development GO:0001701 9.97 TP53 SMAD4 PALB2 ACVR1B
4 negative regulation of gene expression GO:0010629 9.96 TP53 MIR21 MIR17 MIR155 ACVR1B
5 regulation of cell proliferation GO:0042127 9.94 TP53 SMAD4 MIR155 BRCA1
6 positive regulation of gene expression GO:0010628 9.91 TP53 MIR34A MIR21 MIR155 KRAS BRCA1
7 cellular response to hypoxia GO:0071456 9.89 TP53 MIR34A MIR17 MIR155
8 negative regulation of cell growth GO:0030308 9.88 TP53 STK11 SMAD4 ACVR1B
9 negative regulation of angiogenesis GO:0016525 9.87 MIR34A MIR21 MIR15A MIR10A
10 double-strand break repair via homologous recombination GO:0000724 9.85 PALB2 BRCA2 BRCA1
11 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.85 SMAD4 MIR221 MIR21
12 double-strand break repair GO:0006302 9.83 TP53 BRCA2 BRCA1
13 negative regulation of protein kinase B signaling GO:0051898 9.81 MIR34C MIR34B MIR34A
14 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.8 MIR221 MIR21 MIR17
15 positive regulation of epithelial to mesenchymal transition GO:0010718 9.79 SMAD4 MIR221 MIR21
16 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.77 MIR96 MIR34A MIR15A
17 positive regulation of cell cycle arrest GO:0071158 9.71 TP53 MIR34A BRCA1
18 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.71 MIR483 MIR221 MIR15A MIR155
19 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.7 MIR483 MIR15A MIR155
20 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.68 MIR17 MIR155
21 regulation of protein kinase B signaling GO:0051896 9.68 STK11 MIR21
22 inner cell mass cell proliferation GO:0001833 9.68 PALB2 BRCA2
23 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.67 MIR34A MIR21 MIR15A
24 positive regulation of metalloendopeptidase activity GO:1904685 9.66 MIR21 MIR17
25 negative regulation by host of viral genome replication GO:0044828 9.66 MIR221 MIR155
26 positive regulation of histone H3-K9 acetylation GO:2000617 9.65 SMAD4 BRCA1
27 negative regulation of regulatory T cell differentiation GO:0045590 9.65 MIR21 MIR155
28 positive regulation of cellular senescence GO:2000774 9.65 MIR34A MIR10A KRAS
29 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.63 MIR21 MIR17
30 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.63 MIR221 MIR155
31 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.63 TP53 MIR34A MIR17
32 positive regulation of connective tissue replacement GO:1905205 9.62 MIR34C MIR34B MIR34A MIR155
33 negative regulation of cell adhesion molecule production GO:0060354 9.61 MIR221 MIR155
34 chordate embryonic development GO:0043009 9.61 BRCA2 BRCA1
35 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.61 TP53 BRCA2 BRCA1
36 negative regulation of vascular wound healing GO:0061044 9.58 MIR34A MIR155
37 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.56 MIR34C MIR34B MIR17 MIR155
38 negative regulation of sprouting angiogenesis GO:1903671 9.55 MIR34C MIR34B MIR34A MIR221 MIR17
39 miRNA mediated inhibition of translation GO:0035278 9.5 MIR96 MIR483 MIR221 MIR21 MIR17 MIR15A
40 gene silencing by miRNA GO:0035195 9.32 MIR96 MIR483 MIR34C MIR34A MIR221 MIR21

Molecular functions related to Pancreatic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.28 MIR96 MIR483 MIR34A MIR221 MIR21 MIR17
2 LRR domain binding GO:0030275 8.96 STK11 KRAS

Sources for Pancreatic Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....